CHC – The Cancer & Hematology Centers

C4481001 ( Pfizer)

Description:  A Phase 1, Open-Label, Multi-center, Dose Escalation And Dose

Expansion Study To Evaluate the Safety, Tolerability, pharmacokinetics, and Preliminary Evidence of Anti-Tumor Activity of PF-07284892 (Arry-558) As a Single Agent and In Combination Therapy In Participants With Advanced Solid Tumors


Target Patient Population:   Currently in Monotherapy Dose Escalation for : ALK-positive advanced NSCLC, CRC with BRAF V600E mutation, or RAS-mutant, NF1-mutant, or BRAF class 3-mutant solid tumor (other tumors considered in Part 1 if rationale provided)

After 2 cycles, the drug is given in combination with Lorlatinib, Encorafenib and Cetuximab, or Binimetinib (depending on the mutation involved)

Study Design:  Drug is given orally twice weekly.